These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31369088)

  • 21. The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.
    Neary M; Lamorde M; Olagunju A; Darin KM; Merry C; Byakika-Kibwika P; Back DJ; Siccardi M; Owen A; Scarsi KK
    Clin Pharmacol Ther; 2017 Sep; 102(3):529-536. PubMed ID: 28187506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.
    Meng X; Yin K; Wang J; Dong P; Liu L; Shen Y; Shen L; Ma Q; Lu H; Cai W
    PLoS One; 2015; 10(6):e0130583. PubMed ID: 26107645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.
    Habtewold A; Aklillu E; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Owen JS
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.
    Habtewold A; Amogne W; Makonnen E; Yimer G; Riedel KD; Ueda N; Worku A; Haefeli WE; Lindquist L; Aderaye G; Burhenne J; Aklillu E
    J Antimicrob Chemother; 2011 Oct; 66(10):2350-61. PubMed ID: 21846671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.
    Leger P; Dillingham R; Beauharnais CA; Kashuba AD; Rezk NL; Fitzgerald DW; Pape JW; Haas DW
    J Infect Dis; 2009 Sep; 200(6):955-64. PubMed ID: 19659438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms.
    Lindfelt T; O'Brien J; Song JC; Patel R; Winslow DL
    Ann Pharmacother; 2010 Oct; 44(10):1572-8. PubMed ID: 20841522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.
    Dhoro M; Zvada S; Ngara B; Nhachi C; Kadzirange G; Chonzi P; Masimirembwa C
    BMC Pharmacol Toxicol; 2015 Mar; 16():4. PubMed ID: 25889207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
    Mukonzo JK; Okwera A; Nakasujja N; Luzze H; Sebuwufu D; Ogwal-Okeng J; Waako P; Gustafsson LL; Aklillu E
    BMC Infect Dis; 2013 Jun; 13():261. PubMed ID: 23734829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP2B6 Genotype-Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers.
    Metzger IF; Dave N; Kreutz Y; Lu JBL; Galinsky RE; Desta Z
    Clin Transl Sci; 2019 Nov; 12(6):657-666. PubMed ID: 31339646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.
    Gallien S; Journot V; Loriot MA; Sauvageon H; Morlat P; Reynes J; Reliquet V; Chêne G; Molina JM;
    HIV Med; 2017 Sep; 18(8):537-545. PubMed ID: 28145050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.
    Robarge JD; Metzger IF; Lu J; Thong N; Skaar TC; Desta Z; Bies RR
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.
    Luo M; Chapel S; Sevinsky H; Savant I; Cirincione B; Bertz R; Roy A
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3676-86. PubMed ID: 27067333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
    Chaivichacharn P; Avihingsanon A; Manosuthi W; Ubolyam S; Tongkobpetch S; Shotelersuk V; Punyawudho B
    Clin Ther; 2020 Jul; 42(7):1234-1245. PubMed ID: 32451120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry.
    Wang PF; Neiner A; Kharasch ED
    Drug Metab Dispos; 2019 Oct; 47(10):1195-1205. PubMed ID: 31324697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.
    Chang JL; Lee SA; Tsai AC; Musinguzi N; Muzoora C; Bwana B; Boum Y; Haberer JE; Hunt PW; Martin J; Bangsberg DR; Kroetz DL; Siedner MJ
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):982-992. PubMed ID: 29973058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
    Heil SG; van der Ende ME; Schenk PW; van der Heiden I; Lindemans J; Burger D; van Schaik RH
    Ther Drug Monit; 2012 Apr; 34(2):153-9. PubMed ID: 22354160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of CYP2B6-516G > T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand.
    Aurpibul L; Chotirosniramit N; Sugandhavesa P; Kosashunhanan N; Thetket S; Supindham T; Piyamongkol W; Supparatpinyo K
    Curr HIV Res; 2012 Dec; 10(8):653-60. PubMed ID: 22950382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers.
    Zubiaur P; Saiz-Rodríguez M; Ochoa D; Belmonte C; Román M; Mejía G; Martín-Vilchez S; Abad-Santos F
    Pharmacogenomics J; 2020 Apr; 20(2):235-245. PubMed ID: 31628422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites.
    Decloedt EH; Sinxadi PZ; van Zyl GU; Wiesner L; Khoo S; Joska JA; Haas DW; Maartens G
    J Antimicrob Chemother; 2019 Mar; 74(3):699-709. PubMed ID: 30535366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efavirenz pharmacogenetics in a cohort of Italian patients.
    Cusato J; Tomasello C; Simiele M; Calcagno A; Bonora S; Marinaro L; Leggieri A; Allegra S; Di Perri G; D'Avolio A
    Int J Antimicrob Agents; 2016 Feb; 47(2):117-23. PubMed ID: 26774523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.